Gen Era Diagnostics and EDH Nuclear Medicine and Healthcare Services have joined forces by bringing together their expertise in personalized diagnosis and treatment.

Gen Era, a leading genomics services company for Next Generation Sequencing (NGS), Molecular Biology, Bioinformatics and Life Sciences, moving on to shape the future of these projects from today, with technical knowledge and protocols covering a wide range of applications, as one of the first service providers in Turkey in the field of NGS. Expanding the geographies, it serves by offering to its stakeholders short turnaround times, competitive pricing and unmatched scientific support, Gen Era reinforces its pioneering role in the development of innovative products with RefGen, which it has recently acquired.

EDH, the authorized representative of the world’s leading companies in the nuclear medicine industry in more than 20 countries; operates in Turkey, Europe and the Middle East with its personalized cancer diagnosis and treatment products. In addition to its sales, distribution and technical service activities of radiopharmaceutical production, quality control and imaging equipment, EDH offers leading products used in targeted therapy to the use of researchers thanks to its business partners in the USA and continues to develop new products with its business partners in Europe.

With the synergy brought by the merger, Gen Era will strengthen its position in the global market with bioinformatics software, Next Generation Sequencing solutions and niche products in personalized oncology to complete the value chain in the fields of molecular/genetic diagnosis and targeted therapy, which are becoming increasingly important in today’s world. The goal is to be more active in markets outside Turkey with a fast and strong geographical growth strategy, including potential inorganic growth in the near future. After the restructuring, activities in the field of nuclear medicine and radiotheranostics will continue under the existing EDH brand.

Gen Era Managing Partners Alper Emrah İşeri and Murat Topaloğlu commented regarding the merger:

“While we increase our knowledge in niche areas thanks to the complementary products and services of EDH and Gen Era, we believe that this merger will add great strength and value to us in our journey to open up to global markets. In addition to the products offered to the market by EDH, especially in the field of personalized oncology, we are excited to be able to offer innovative products to all our stakeholders with a holistic approach and the use of our diagnostic solutions that we are developing within Refgen. In addition, we think that the visionary approach of both companies, good relations with their stakeholders and having core values ​​such as business ethics will be very important for the success of the new structure.”

EDH Founder and General Manager Hasan Ulaş Özcan also commented:

“We are very happy to be a part of the Gen Era family, which has gained a well-deserved appreciation in the national and international arena for its extraordinary development and achievements in the fields of genetics and life sciences. We are excited to start our journey with the aim of being among the important players of the future healthcare within Gen Era thanks to our team especially experienced in the nuclear medicine, medical device and clinical research sectors who has developed long-term relationships with global players.”

www.gen-era.com.tr   |    www.edhmed.com

Hasan Ulaş Özcan, General Manager of EDH Nuclear Medicine & Healthcare Services and experienced executive served Nuclear Medicine society, has been honored to serve as Ambassador of the Oncidium foundation in Turkey.

“I have been personally trying hard to spread the word and reach more patients who may benefit from the Radiotheranostics and create awareness in the society. At a certain point I thought to serve community in a better way by joining our efforts with the people sharing the same passion under the umbrella of the Oncidium foundation. Together with Oncidium foundation, we aim to leverage Radiotheranostics as alternatives for cancer therapy and providing support to accelerate global access. This is a voluntary assignment and the collective efforts we will be having to create a bigger impact is priceless. I appreciate and thank Oncidium foundation team allowing me to be a part of this great cause” commented Hasan Ulaş Özcan. 

“We are very honored to have Mr. Hasan Ulaş Özcan as part of the Oncidium foundation Ambassadors network. Our mission is to support and promote the development of Radiotheranostics for cancer therapy, worldwide. Thus, it requires having local representation, notably in Turkey, where Radiotheranostics are becoming more and more available and important” stated Rebecca Lo bue, General Manager of the Oncidium foundation. 

About EDH Nuclear Medicine and Healthcare Services:

EDH is one of the most innovative Service Integrators in the field of Nuclear Medicine and oncology offering state of the art solutions. EDH currently handles sales and marketing of selected radiopharmaceuticals and radioisotopes as well as sales and after sales support of equipment used in Nuclear Medicine and niche segments of oncology. EDH also offers turnkey setup of radiopharmaceutical manufacturing plants and nuclear medicine departments compliant to EU/USFDA GMP.

About the Oncidium foundation:

The Oncidium foundation was created in 2011 by Dr. Richard Zimmermann to support and promote the development of Radiotheranostics worldwide. The foundation’s priorities include raising awareness about Radiotheranostics among patients, practitioners, and the general public; investing in research and scholarships; encouraging the development of new radiopharmaceuticals for therapy; supporting clinical best practice and enhancing access for patients, globally.